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Abstract
Introduction: Glucocorticoids are widely prescribed drugs. In the human body, glucocorticoid is the main stress
hormone and controls a variety of physiological and cellular processes, including metabolism and immune
response. It belongs to the same steroid superfamily as estrogens, which are known to play a role in breast cancer.
However, the effect of glucocorticoid use on the risk of breast cancer is not clear.
Methods: We conducted a case-control study using population-based medical databases from Northern Denmark
(1.8 million inhabitants) to investigate the association between glucocorticoid prescriptions and breast cancer risk.
The study included 9,488 incident breast cancer cases diagnosed between 1994 and 2008 and 94,876 population
controls. We estimated the odds ratios (ORs) and 95% confidence intervals (CIs) associating glucocorticoid use with
breast cancer occurrence, controlling for prescriptions of postmenopausal hormone replacement therapy, anti-
diabetics, immunosuppressive drugs, and hospital diagnosis of obesity, diabetes, chronic pulmonary diseases and
autoimmune diseases.
Results: We found no effect on breast cancer risk in ever users (> 2 prescriptions) of any glucocorticoids (adjusted
odds ratio (aOR) = 1.0; 95% CI: 0.96, 1.1), systemic glucocorticoids (aOR = 1.0; 95% CI: 0.96, 1.1), or inhaled
glucocorticoids (aOR = 1.0; 95% CI: 0.95, 1.1), each compared to never users of any glucocorticoids. Associations for
recent use (preceding two years) and former use (more than two years earlier) were near null in all dose categories
(low, medium and high number of prescriptions). Intensity of systemic glucocorticoid use (cumulative prednisolone
equivalent doses), regardless of duration (< 1, 1 to 5, 5+ years), was also not associated with breast cancer risk.
Conclusions: Overall, our study provides no evidence that glucocorticoid use affects the risk of breast cancer.
Introduction
Glucocorticoid is an adrenocortical hormone, belonging to
the same steroid superfamily as estrogen, which is known
to play a role in breast cancer risk [1]. Glucocorticoids
mediate most of their effects through the intracellular glu-
cocorticoid receptor (GR), which subsequently modulates
downstream gene regulation [2]. The GR is expressed in
breast tissue and has been shown to be involved in normal
breast development during pregnancy [3]. In the human
body, glucocorticoid is the main stress hormone and con-
trols a variety of physiological and cellular processes
including metabolism, cell growth, apoptosis, and immune
response [2]. Thus, it could potentially play a role in the
risk of breast cancer by several mechanisms.
Synthetic glucocorticoids affect immune function and
are commonly used as anti-inflammatory and immuno-
suppressive therapy in diseases such as asthma, chronic
obstructive pulmonary disease (COPD), inflammatory
bowel disease (IBD), inflammatory arthritis, and other
connective tissue disorders [4]. The immune system has
a role in preventing cancer development and progres-
sion [5,6], so suppression of the immune system may
promote tumor development. However, the role of the
immune system in cancer is dual and complex, since it
may also promote tumor growth [5]. In addition,
decreased glucose tolerance, a well-known side effect of
glucocorticoids [4], has been suggested to promote
mammary carcinogenesis [7-9].* Correspondence: vrelits@gmail.com
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To our knowledge, only one study has previously been
published on the relation between glucocorticoid use
and breast cancer risk [10]. Our previous study included
nearly 33,000 women, ascertained prescriptions for sys-
temic glucocorticoids between 1989 and 1996, ascer-
tained breast cancers until 1998, and recorded a total of
367 breast cancer cases. We reported no association
between glucocorticoid prescriptions and breast cancer
risk. Due to a relatively short average follow-up time
(mean 5.8 years), we were not able to investigate the
effect of long-term use. Also, we were only able to con-
trol for age as a potential confounder.
A recent review called for further research investigat-
ing the potential association between glucocorticoid use
and breast cancer risk, criticizing our previous study for
lack of clinical details and the possibility of confounding
[11]. We, therefore, conducted a large population-based
case-control study with prospectively collected prescrip-
tion data to examine the association between glucocorti-
coid use and breast cancer risk. In addition to following
a larger population over a longer period, we have
extended our previous study [10] by incorporating more
information on potential confounders, such as parity,
age at first birth, use of postmenopausal hormone repla-
cement therapy (HRT), anti-diabetic medicine, immuno-
suppressive drugs, any history of hospital diagnosed
obesity, diabetes, COPD, asthma, rheumatoid arthritis




We conducted this population-based case-control study
among female residents of the Central and North Den-
mark Regions between 1 February 1994 and 31 Decem-
ber 2008. Together, these regions represent about one-
third of the Danish population (approximately 1.8 mil-
lion inhabitants). The Danish National Health Service
provides tax-supported health-care to all residents of the
country and refunds part of the patients’ expenditures
on most physician-prescribed drugs, including glucocor-
ticoids [12].
All health-related services are registered to individual
patients by use of their civil personal registration (CPR)
number, assigned to all Danish citizens since 1968 by
the Danish Civil Registration System (CRS). This num-
ber encodes gender and date of birth [13] and facilitates
accurate individual-level linkage between population-
based registries.
The Danish regions are served by pharmacies
equipped with computerized accounting systems
through which data are sent to a regional prescription
database hosted by Aarhus University [12], with key
information about prescriptions for refundable drugs.
Thus, the prescription database includes information on
each patient’s CPR number; the type and quantity of
drug prescribed according to the Anatomical Therapeu-
tic Chemical classification system (ATC), and the date
the prescription was filled [12,14]. The Danish regions
were until 1 January 2007 divided into counties. Because
the different counties started contributing data to the
prescription database at different times, they differ with
respect to the earliest availability of prescription data,
with the earliest being 1989 [12]. To ensure that we had
at least minimal prescription data history for each case
and their corresponding controls, we only included
women who had more than 5 years of prescription his-
tory before their index date (as defined below). Women
who were resident in the study area for less than five
years before index date were excluded from the source
population, as were women with any malignant cancer
diagnosis before their index dates (except non-mela-
noma skin cancers).
Cases
The sample size was determined by using the Danish
Cancer Registry (DCR) to identify all women with an
incident diagnosis of breast cancer in the region during
the study period (see Additional file 1 for International
Classification of Diseases (ICD) codes). The DCR has
recorded all incident cancers through 31 December
2008 [15] and has near 100% completeness for breast
cancer diagnosis [16]. With this sample size, our study
had 90% power to detect an odds ratio of 1.1 or greater.
Population controls
Controls were identified using the CRS [13,17]. A pool
of eligible individuals with the same birth year and
county/region of residence as each breast cancer patient
was sampled from the general-population among all
women alive and free of breast cancer on the date of
the matched case’s breast cancer diagnosis. This date of
diagnosis, therefore, served as the index date for the
case and all of the controls matched to the case. Ten
individuals from this pool were randomly selected for
each case. All eligible controls were included when the
risk-set of matched controls included fewer than ten
individuals.
Data collection
The prescription database [12] was used to identify all pre-
scriptions before index date for systemic (oral and
injected), inhaled and local-acting glucocorticoids with
intestinal anti-inflammatory effect (’local glucocorticoids’
hereafter). The following preparations were available and
prescribed during the study period (see Additional file 1
for ATC codes): betamethasone, dexamethasone, methyl-
prednisolone, prednisolone, prednisone, triamcinolone,
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cortisone, hydrocortisone, beclomethason, budesonide, flu-
nisolide, fluticasone, and mometasone.
Potential confounding prescription drugs
The prescription database also provided information on
use of the following potential confounding drugs before
the index date (see Additional file 1 for ATC codes):
postmenopausal HRT [18], anti-diabetics [19], and use
of immunosuppressive drugs as a marker of immune-
related disease.
Potential confounding diseases
The Danish National Patient Registry (DNPR) contains
information about all non-psychiatric hospital admis-
sions since 1977, and since 1995 also outpatient visits
[20]. From the DNPR we retrieved data on hospital
diagnoses of the following diseases before the index
date: obesity, diabetes, COPD, asthma, RA, IBD (ulcera-
tive colitis or Crohn’s disease), and a list of ‘other auto-
immune diseases’ (see Additional file 1 for the list of
diseases and associated ICD codes).
Other potential confounders
To obtain information about parity and age at first birth
we used the CRS [13]. In the CRS, the CPR numbers of
parents are linked to their child, as long as the child
lived with the parents in 1968 or later. We limited the
analysis adjusted for parity and age at first birth to
women born later than 1949, for whom the CRS allows
reconstruction of childbearing history with better than
95% completeness [21].
Analytic variables
We categorized glucocorticoid use as never versus ever
use. Ever users were further subdivided into two dose
categories: one or two prescriptions or more than two
prescriptions. We examined the association of overall
glucocorticoid use with breast cancer and then exam-
ined the association of systemic and inhaled glucocorti-
coid use separately. To examine the temporality of
glucocorticoid use and the risk of breast cancer, we
divided ever use into recent use (only prescriptions
within two years of the index date) and former use (pre-
scriptions earlier than two years of the index date). In
the group of any glucocorticoid users we further divided
the number of prescriptions into low (one or two pre-
scriptions), medium (three to nine) and high (more than
nine). We based these cut-offs on the distribution of
prescription counts among the controls with more than
two prescriptions.
To examine whether breast cancer risk was associated
with the intensity and duration of glucocorticoid use, we
restricted the analyses to systemic glucocorticoid users
and calculated prednisolone equivalent cumulative doses
based on the equivalency table in Kelly’s Textbook of
Rheumatology [22] and grouped into the four categories:
< 200 mg, 200 to 399 mg, 400 to 999 mg and ≥ 1,000
mg (for calculations see Additional file 2). The duration
was defined as the number of days from the date of the
first prescription to the date of the last prescription,
plus the duration of the last prescription (estimated to
be on average 30 days). We divided the duration of glu-
cocorticoid use into short-term (less than one year),
medium-term (one to five years), and long-term (more
than five years).
The covariates ever use of immunosuppressive drugs,
ever use of postmenopausal HRT, COPD, asthma, IBD,
obesity, and RA were coded individually as dichotomous
variables. Other autoimmune diseases (see Additional
file 1) were merged into a dichotomous variable. Since
diabetes and metformin use may have counteracting
effects on breast cancer risk [19], we coded diabetes and
anti-diabetic medicine use as a categorical variable with
three possible levels: no diabetes or use of anti-diabetic
medicine, diabetes or use of anti-diabetic medicine with
ever use of metformin, and diabetes or use of anti-dia-
betic medicine without ever use of metformin.
Statistical analysis
We computed the frequency and proportion of cases
and controls within categories of demographic variables
and covariates.
In all analyses, we used never use of any glucocorti-
coids as the reference group. For the use of any gluco-
corticoids, systemic glucocorticoids, and inhaled
glucocorticoids, we stratified by all covariates and calcu-
lated crude and stratum-specific odds ratios (ORs) to
evaluate potential confounding and effect measure mod-
ification. We used conditional logistic regression analysis
to compute crude and adjusted ORs (aORs) and their
associated confidence intervals (95% CI), with simulta-
neous adjustment for the use of postmenopausal HRT,
immunosuppressive drugs, hospital diagnosed obesity,
diabetes (plus/minus a history of metformin use),
COPD, asthma, IBD, RA and ‘other autoimmune dis-
ease.’ Since we used risk set sampling of controls, the
ORs are unbiased estimates of the corresponding inci-
dence rate ratio in the underlying population [23]. We
report estimates of association stratified by age cate-
gories (< 45, 45 to 55 and > 55, as estimated ranges for
pre-, peri- and post-menopausal status). In the group of
women < 45, we were able to make additional adjust-
ment for parity and age at first birth, using the com-
bined variable (see Table 1).
We used Stata 11.0 (StataCorp LP, College Station,
TX, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC,
USA) for the data analyses. This study was approved by
the Danish Data Protection Agency (reference #2004-
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Table 1 Frequency distribution of cases and matched population controls in North Jutland County between 1994-
2008, Aarhus County between 2001-2008, and Viborg- and Ringkjøbing Counties between 2003-2008
Characteristics Cases (N = 9,488) Controlsa (N = 94,876)
N % N %
Age at index datea
< 45 899 9.5 9,072 9.6
45 to 55 1,932 20 19,108 20
> 55 6,657 70 66,696 70
County at index datea, b
North Jutland 4,424 47 44,236 47
Aarhus 3,168 33 31,680 33
Viborg 931 10 9,310 10
Ringkjøbing 965 10 9,650 10
Calendar year at index datea
1994-1998 1,253 13 12,530 13
1999-2003 2,910 31 29,100 31
2004-2008 5,325 56 53,246 56
Use of any glucocorticoids
Never 6,692 71 68,064 72
≤ 2 prescriptions ever 1,452 15 13,891 15
> 2 prescriptions ever 1,344 14 12,921 14
Use of other immunosuppressive drugs
Never 9,395 99 93,880 99
Ever 93 1.0 996 1.0
Use of postmenopausal hormone replacement therapy
Never 7,252 76 76,919 81
Ever 2,236 24 17,957 19
Hospital diagnosed diabetes or ever use of anti-diabetic medicine
Never 8,961 94 90,180 95
Yes & never metformin 312 3.3 2,655 2.8
Yes & ever metformin 215 2.3 2,041 2.2
Hospital diagnosed chronic obstructive pulmonary disease
No 9,093 96 91,161 96
Yes 395 4.2 3,715 3.9
Hospital diagnosed asthma
No 9,266 98 92,583 98
Yes 222 2.3 2,293 2.4
Hospital diagnosed inflammatory bowel disease
No 9,407 99 94,117 99
Yes 81 0.9 759 0.8
Hospital diagnosed rheumatoid arthritis
No 9,392 99 93,733 99
Yes 96 1.0 1,143 1.2
Other autoimmune diseasesc
No 9,086 96 91,201 96
Yes 402 4.2 3,675 3.9
Hospital diagnosed obesity
No 9,240 97 92,512 98
Yes 248 2.6 2,364 2.5
Age at first birth in women born later than 1949 (n = 31,130)d
Nulliparous 344 12 3,373 12
< 25 1,284 45 13,845 49
25-30 885 31 8,345 30
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41-4693). According to Danish law, registry-based stu-
dies such as this one do not require further approval by
an ethical review board or informed consent by the
members of the study population.
Results
We identified 9,488 breast cancer cases and 94,876
population controls. Median age at the index date was
62.1 years. Characteristics of cases and controls are
shown in Table 1. As expected, a higher proportion of
cases than controls had ever used postmenopausal HRT
by their index date (24% versus 19%). In the subgroup
of women born later than 1949 (n = 31,130), a lower
proportion of cases than controls had a first birth before
age 25 (45% versus 49%) and had three or more children
(25% versus 27%). In all other characteristics, there were
no important differences between cases and controls.
We found no effect on breast cancer risk in ever users
(> 2 prescriptions) of any glucocorticoids compared to
never users (aOR = 1.0; 95% CI: 0.96, 1.1). The associa-
tion among former users with a high number of prescrip-
tions (> 9) was null (aOR = 1.0; 95% CI: 0.93, 1.1). In
addition, among recent users who only had prescriptions
within the two years before their index date, we found
null associations. Restricting the analysis to systemic or
inhaled glucocorticoid use also showed no associations.
Ever use (> 2 prescriptions) of systemic (aOR = 1.0; 95%
CI: 0.96, 1.1) or inhaled glucocorticoids (aOR = 1.0; 95%
CI: 0.95, 1.1), each compared to never use of any gluco-
corticoids, were both null (Table 2). Intensity of systemic
glucocorticoid use (cumulative prednisolone equivalent
doses), regardless of duration (< 1, 1 to 5, 5+ years),
showed no pattern of association (Table 3). Stratifying
into estimates of pre-, peri-, and post-menopausal status
by age group also did not show any pattern of associa-
tion. In the subgroups of women < 45 years old (Table 4)
and all women born later than 1949 (n = 31,130), addi-
tional adjustment for parity and age at first birth did not
change our overall estimates of null association. In the
latter group, the aOR for > 2 glucocorticoid prescriptions
ever, compared to never, was 1.0 (95% CI 0.88, 1.2).
Discussion
Overall, this population-based case-control study of
more than 100,000 women provided no evidence of an
association between glucocorticoid use and breast can-
cer risk. The null association was consistent when divid-
ing the use of glucocorticoids into recent and former
use, intensity and duration of use, and also consistent
with our previous study [10]. Our results answer the
need for research on the role of glucocorticoids in
breast cancer risk, which has not been well studied [11].
Our study has several strengths. The uniformly orga-
nized Danish healthcare system with complete hospital
history and access to appropriate population controls
allows a population-based case-control design. The use
of population-based prescription registries, with a com-
pleteness approaching 100% [12,14] ensured unbiased
assessment of exposure data preceding breast cancer
diagnosis and the registry source eliminated recall bias.
In all our analyses, we included only persons with at
least 5 years of prescription history, thus potential bias
due to left censoring of exposure information was
reduced compared with the earlier study [10].
Our study also had limitations. We had no data
regarding adherence with prescriptions, potentially
Table 1 Frequency distribution of cases and matched population controls in North Jutland County between 1994-
2008, Aarhus County between 2001-2008, and Viborg- and Ringkj?ø?bing Counties between 2003-2008 (Continued)
> 30 317 11 2,737 10
Parity in women born later than 1949 (n = 31,130)d
Nulliparous 344 12 3,373 12
1 child 445 16 4,170 15
2 children 1,341 47 13,005 46
≥ 3 children 700 25 7,752 27
Combined parity & age (year) at first birth in women born later than 1949 (n = 31,130)d
Nulliparous 344 12 3,373 12
1 child & < 25 y 154 5.4 1,444 5.1
2 children & < 25 y 658 23 6,956 25
≥ 3 children & < 25 y 472 17 5,445 19
1 child & ≥ 25 y 291 10 2,726 9.6
2 children & ≥ 25 y 683 24 6,049 21
≥ 3 children & ≥ 25 y 228 8.1 2,307 8.2
aControls were matched to cases on county/region of residence and birth year. bThe counties were merged into the two regions in 2007. Thus, from 2007 to
2008 the women were instead matched on former county. The higher proportion of people in North Jutland County was a result of longer prescription history.
cSee Additional file 1 for the list of hospital-diagnosed other autoimmune diseases. dTo assure complete data on every birth of the woman we made a subgroup
of women born later than 1949 (n = 31,130).
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leading to non-differential misclassification of some
non-users as users. However, our drug exposure assess-
ment was based on redeemed prescriptions, and because
patients had to pay a proportion of the drug cost, our
estimates are likely to reflect actual use, especially in
women with more than two prescriptions. In support of
this expectation, a validation study on postmenopausal
HRT by Danish women showed good agreement
between self-reported use and prescription data in the
registry [24]. We also had no information on body mass
index, alcohol consumption or family history of breast
cancer, and other factors that may impact the risk of
breast cancer [25]. To confound our results substantially
they would also have to be related to glucocorticoid use
Table 2 Number of prescriptions (pres.) and temporality of any glucocorticoid (GC) use, systemic GC use and inhaled









N % N %
Any GC use
Never use 6,692 71 68,064 72 reference reference
Ever use
≤ 2 pres. 1,452 15 13,891 15 1.0 0.98, 1.1
> 2 pres. 1,344 14 12,921 14 1.0 0.96, 1.1
Recent usec
≤ 2 pres. 284 3.0 2,949 3.1 0.96 0.84, 1.1
3 to 9 pres. 72 0.8 781 0.8 0.93 0.73, 1.2
> 9 pres. 13 0.1 156 0.2 0.82 0.46, 1.4
Former used
≤ 2 pres. 1,168 12 10,942 12 1.1 0.99, 1.1
3 to 9 pres. 655 6.9 6,142 6.5 1.0 0.96, 1.1
> 9 pres. 604 6.4 5,842 6.2 1.0 0.93, 1.1
Systemic GC use
Never use of any GC 6,692 71 68,064 72 reference reference
Only inhaled/local GC use 451 4.8 4,401 4.6 1.0 0.93, 1.1
Ever use of systemic GC
≤ 2 pres. 1,437 15 13,719 15 1.0 0.98, 1.1
> 2 pres. 908 10 8,692 9.1 1.0 0.96, 1.1
Recent systemic usec
≤ 2 pres. 278 2.9 2,903 3.1 0.95 0.84, 1.1
> 2 pres. 64 0.7 705 0.7 0.91 0.71, 1.2
Former systemic used
≤ 2 pres. 1,159 12 10,816 11 1.1 0.99, 1.1
> 2 pres. 844 8.9 7,987 8.4 1.0 0.96, 1.1
Inhaled GC use
Never use of any GC 6,692 71 68,064 72 reference reference
Only systemic/local GC use 1,886 20 17,951 19 1.0 0.98, 1.1
Ever users of inhaled GC
≤ 2 pres. 317 3.4 3,223 3.4 1.0 0.87, 1.1
> 2 pres. 593 6.2 5,638 6.0 1.0 0.95, 1.1
Recent inhaled usec
≤ 2 pres. 84 0.9 770 0.8 1.1 0.86, 1.4
> 2 pres. 38 0.4 453 0.5 0.83 0.59, 1.2
Former inhaled used
≤ 2 pres. 233 2.5 2,453 2.6 0.94 0.82, 1.1
> 2 pres. 555 5.8 5,185 5.5 1.1 0.97, 1.2
aControls were matched to cases on county of residence and birth year. bAnalysis adjusted for any use of postmenopausal hormone replacement therapy or
‘other immunosuppressive drugs’ before index date, and any hospital diagnosis of obesity, diabetes (+/- metformin use), chronic obstructive pulmonary disease,
asthma, inflammatory bowel disease, rheumatoid arthritis or ‘other autoimmune disease’ before index date. cRecent use: gucocorticoid use only within two years
of diagnosis, and never a former user. dFormer use: Glucocorticoid use earlier than within two years of diagnosis.
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Table 3 Duration and intensity of systemic glucocorticoid (GC) cumulative doses in milligram (mg) prednisolone
equivalent dosesa and odds ratio of breast cancer
Characteristics Cases (N = 9,488) Controlsb
(N = 94,876)
Odds Ratioc 95% Confidence Interval
N % N %
Never any GC use 6,692 71 68,064 72 reference reference
Only inhaled/local use 451 4.8 4,401 4.6 1.0 0.93, 1.1
Short-term (< 1 year of use)d
< 200 mg 1,237 13 11,830 12 1.0 0.97, 1.1
200 to 399 mg 94 0.99 990 1.0 0.93 0.75, 1.2
400 to 999 mg 21 0.22 242 0.26 0.88 0.57, 1.4
≥ 1000 mg 15 0.16 93 0.10 1.6 0.90, 2.8
Medium-term (1 to 5 years of use)d
< 200 mg 289 3.1 2,805 3.0 1.0 0.89, 1.2
200 to 399 mg 138 1.5 1,166 1.2 1.2 0.97, 1.4
400 to 999 mg 67 0.71 545 0.57 1.2 0.93, 1.6
≥ 1000 mg 20 0.21 273 0.29 0.73 0.46, 1.2
Long-term (> 5 years of use)d
< 200 mg 170 1.8 1,683 1.8 1.0 0.85, 1.2
200 to 399 mg 123 1.3 1,141 1.2 1.1 0.87 1.3
400 to 999 mg 96 1.0 1,053 1.1 0.89 0.72, 1.1
≥ 1000 mg 75 0.79 590 0.62 1.2 0.96, 1.6
aFor calculations see Additional file 2. bControls were matched to cases on county of residence and birth year. cAnalysis adjusted for any use of postmenopausal
hormone replacement therapy or ‘other immunosuppressive drugs’ before index date and any hospital diagnosis of obesity, diabetes (+/- metformin use), chronic
obstructive pulmonary disease, asthma, inflammatory bowel disease, rheumatoid arthritis or ‘other autoimmune disease’ before the index date. dDuration was
calculated as time between the first and the last systemic glucocorticoid prescription (plus 30 days from the last prescription), and then divided into short-,
medium- and long-term use.









N % N %
Age < 45 (pre-menopausal)
Never use 744 83 7,353 81 reference reference
Ever use
≤ 2 prescriptions 98 11 1000 11 0.97c 0.78, 1.2c
> 2 prescriptions 57 6.4 719 7.9 0.83c 0.61, 1.1c
Age 45 - 55 (peri-menopausal)
Never use 1,488 77 14,450 76 reference reference
Ever use
≤ 2 prescriptions 248 13 2,757 14 0.86 0.75, 0.99
> 2 prescriptions 196 10 1,901 10 0.96 0.80, 1.1
Age > 55 (post-menopausal)
Never use 4,460 67 46,261 69 reference reference
Ever use
≤ 2 prescriptions 1,106 17 10,134 15 1.1 1.0, 1.2
> 2 prescriptions 1,091 16 10,301 15 1.1 0.98, 1.1
aControls were matched to cases on county of residence and birth year. bAnalysis was adjusted for any use of postmenopausal hormone replacement therapy or
‘other immunosuppressive drugs’ before index date and any hospital diagnosis of obesity, diabetes (+/- metformin use), chronic obstructive pulmonary disease,
asthma, inflammatory bowel disease, rheumatoid arthritis or ‘other autoimmune disease’ before the index date. c Analyses were additionally adjusted for parity
and age at first birth. Without the additional adjustment the adjusted odds ratios for ≤ 2 or > 2 prescriptions were 0.97 (95% CI: 0.77, 1.2) and 0.83 (95% CI: 0.61,
1.1), respectively.
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conditional on adjustment for the measured covariates,
which we have no reason to expect.
A more important limitation might be our inability to
examine the impact of glucocorticoid use on breast can-
cer risk by specific breast cancer characteristics such as
hormone receptor status. Studies have addressed the
possibility of cross-talk between estrogen receptors and
glucocorticoid receptors in mammary epithelial cells
[26] and recently in vivo studies have suggested that glu-
cocorticoids may stimulate the expression of the sulfo-
transferase SULT1E1, which plays a role in deactivating
estrogen [27]. Thus, estrogen levels and estrogen recep-
tor expression might well impact the action of glucocor-
ticoids. Glucocorticoid response may also vary due to
glucocorticoid receptor gene polymorphisms. The
increased risk of squamous cell carcinoma in glucocorti-
coid users is more pronounced in the presence of the
allele with the common genetic variant in the glucocor-
ticoid receptor gene, compared with the homozygote
wild types [28] but we were unable to evaluate this
gene-drug interaction. Finally, glucocorticoids increase
the expression of insulin-like growth factor-1 (IGF-1)
receptors [29] and the levels of circulating IGF-1 [30].
IGF-1 receptor expression patterns in epithelial cells of
normal breast tissue biopsies were associated with an
increased risk of subsequent breast cancer [31] and a
meta-analysis from 2010 concluded that circulating IGF-
1 levels are positively related to estrogen-receptor-posi-
tive breast tumors, regardless of menopausal status [32].
Our study did not, however, have measurements of IGF-
1 receptor or circulating IGF-1 available for analyses.
Conclusions
There are several mechanisms by which glucocorticoid
prescriptions might affect breast cancer risk in subpopu-
lations defined by molecular subcharacteristics. Evalua-
tions of these associations would require a study with
detailed biological data. Overall, however, our results
provide no evidence of an increased risk of breast can-
cer in glucocorticoid users compared with never users.
Additional material
Additional file 1: List of primary exposure drugs, cancer diagnosis,
potential confounder drugs and diseases, and associated ICD and
ATC codes. This file contains ATC codes for the primary exposure drugs
and potential confounder drugs, ICD codes for the cancer diagnosis
used, and ICD hospital diagnosis codes for the potentially confounder
diseases.
Additional file 2: Cumulative prednisolone equivalent dose
calculation and list of systemic glucocorticoids with associated
prednisolone conversion factors. This file contains a list of the
prescribed systemic glucocorticoids during the study period, their
associated prednisolone conversion factor used for the calculation, and
presents how we calculated cumulative prednisolone equivalent doses.
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